Kidney transplantation in hepatitis C-positive recipients: does type of induction influence outcomes?
Kidney transplantation in hepatitis C virus-seropositive (HCV+) recipients improves survival compared to staying on the waiting list. A concern for using depleting (versus nondepleting) induction agent during kidney transplantation in HCV+ recipients is the possibility that the associated enhanced immunosuppression might favor the progression of hepatitis C infection, leading to adverse outcomes. Utilizing data from the Organ Procurement and Transplant Network, we identified HCV+ patients ≥ 18 years of age who underwent deceased donor kidney (DDK) transplants from either HCV+ or HCV- donors between 1998 and 2008. Patients were divided into two groups based on the induction type they received during the transplant: depleting agent (rabbit-antithymocyte globulin or alemtuzumab) or nondepleting agent (basiliximab or daclizumab) groups. Unadjusted and adjusted graft and patient survivals (Cox regression) between the groups were compared. A total of 3490 HCV+ DDK recipients were identified (1859 in the depleting and 1631 in the nondepleting groups). When compared to nondepleting agent, adjusted graft (hazard ratio [HR] 1.11, 95% confidence interval [CI] 0.96-1.28, P = .16) and patient (HR 1.15, 95% CI 0.93-1.42, P = .2) survivals were similar with depleting agent induction. HCV donor seropositivity did not adversely impact either graft (HR 1.11, 95% CI 0.96-1.29, P = .17) or patient (HR 1.15, 95% CI 0.93-1.42, P = .2) outcomes. Our analysis supports the practice of transplanting HCV+ donor kidneys into HCV+ recipients to alleviate waiting list burden. Recipient HCV positivity should not influence selection of induction agent.